Literature DB >> 16523530

The ketogenic diet: from molecular mechanisms to clinical effects.

John Freeman1, Pierangelo Veggiotti, Giovanni Lanzi, Anna Tagliabue, Emilio Perucca.   

Abstract

Recent years have witnessed an increased interest from pediatric neurologists, neuropediatricians, epileptologists and general neurologists in the use of the ketogenic diet (KD) for the management of refractory epilepsies, particularly in children and adolescents. This article summarizes current knowledge on various issues related to its use, as discussed at a recent international workshop. Aspects discussed in some detail include (i) the putative mechanisms responsible for the diet's anticonvulsant effects,based on results of biochemical and neurophysiological studies in experimental models; (ii) consensus and controversies on the modalities of initiation of the diet, and different protocols of implementation; (iii) indications and contraindications; (iv) efficacy data, also in relation to seizure type, syndromic form and patients age; (v) adverse effects; (vi) methodological aspects related to assessment of the diet's clinical effects, and perspectives for future research. Overall, the data reviewed indicate that considerable advances have been made in understanding the modes of action of the diet, its efficacy and tolerability profiles and its potential role in different types of epilepsy. Although clinical studies performed to date have important methodological limitations, including suboptimally characterized patients' populations and an uncontrolled design, a number of innovative, prospective randomized study protocols have been recently proposed and are being implemented. The results of these will hopefully provide much needed high-quality information to better define the role of the diet in the treatment algorithms in different epilepsy syndromes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16523530     DOI: 10.1016/j.eplepsyres.2005.10.003

Source DB:  PubMed          Journal:  Epilepsy Res        ISSN: 0920-1211            Impact factor:   3.045


  52 in total

1.  How does altered metabolism lead to seizure control? Partially filling the knowledge gap.

Authors:  Jong M Rho
Journal:  Epilepsy Curr       Date:  2010-11       Impact factor: 7.500

Review 2.  Brain fuel metabolism, aging, and Alzheimer's disease.

Authors:  Stephen Cunnane; Scott Nugent; Maggie Roy; Alexandre Courchesne-Loyer; Etienne Croteau; Sébastien Tremblay; Alex Castellano; Fabien Pifferi; Christian Bocti; Nancy Paquet; Hadi Begdouri; M'hamed Bentourkia; Eric Turcotte; Michèle Allard; Pascale Barberger-Gateau; Tamas Fulop; Stanley I Rapoport
Journal:  Nutrition       Date:  2010-10-29       Impact factor: 4.008

Review 3.  Neuroprotective and disease-modifying effects of the ketogenic diet.

Authors:  Maciej Gasior; Michael A Rogawski; Adam L Hartman
Journal:  Behav Pharmacol       Date:  2006-09       Impact factor: 2.293

Review 4.  Cerebral metabolic adaptation and ketone metabolism after brain injury.

Authors:  Mayumi L Prins
Journal:  J Cereb Blood Flow Metab       Date:  2007-08-08       Impact factor: 6.200

Review 5.  Metabolism and epilepsy: Ketogenic diets as a homeostatic link.

Authors:  Susan A Masino; Jong M Rho
Journal:  Brain Res       Date:  2018-06-06       Impact factor: 3.252

6.  Ketone Bodies as a Possible Adjuvant to Ketogenic Diet in PDHc Deficiency but Not in GLUT1 Deficiency.

Authors:  F Habarou; N Bahi-Buisson; E Lebigot; C Pontoizeau; M T Abi-Warde; A Brassier; K H Le Quan Sang; C Broissand; S Vuillaumier-Barrot; A Roubertie; A Boutron; C Ottolenghi; P de Lonlay
Journal:  JIMD Rep       Date:  2017-05-17

7.  Regulation of brain PPARgamma2 contributes to ketogenic diet anti-seizure efficacy.

Authors:  Timothy A Simeone; Stephanie A Matthews; Kaeli K Samson; Kristina A Simeone
Journal:  Exp Neurol       Date:  2016-08-12       Impact factor: 5.330

8.  The ketogenic diet: uses in epilepsy and other neurologic illnesses.

Authors:  Kristin W Barañano; Adam L Hartman
Journal:  Curr Treat Options Neurol       Date:  2008-11       Impact factor: 3.598

Review 9.  Progress in neuroprotective strategies for preventing epilepsy.

Authors:  Munjal M Acharya; Bharathi Hattiangady; Ashok K Shetty
Journal:  Prog Neurobiol       Date:  2007-12-08       Impact factor: 11.685

10.  Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial.

Authors:  Samuel T Henderson; Janet L Vogel; Linda J Barr; Fiona Garvin; Julie J Jones; Lauren C Costantini
Journal:  Nutr Metab (Lond)       Date:  2009-08-10       Impact factor: 4.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.